Note: This thread is 2362 days old. We appreciate that you found this thread instead of starting a new one, but if you plan to post here please make sure it's still relevant. If not, please start a new topic. Thank you!
AZD7442 PROVENT Phase III prophylaxis trial met primary endpoint in preventing COVID-19
AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.
Here's Rory and Tommy doing the "lefty" challenge....